Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Surgical Wound Infections, Colorectal Surgery
Interventions: standard operating management; Procedure
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: Midazolam, Cefiderocol; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Kidney Disease
Interventions: DyeVert Plus Contrast Reduction System; Device
Lead sponsor: Osprey Medical, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Torrance, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Arthritis, Rheumatoid
Interventions: ABP 798, Rituximab (US), Rituximab (EU); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 27
States / cities: Tuscaloosa, Alabama • Los Angeles, California • Thousand Oaks, California + 24 more

Conditions: Vegetables, Cardiovascular Disease, Blood Pressure
Interventions: Vegetable Juice; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Davis, California

Conditions: Fecal Incontinence
Interventions: Consure 120 Stool Management System; Device
Lead sponsor: Consure Medical Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 44 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity
Interventions: group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition; Behavioral · Drug · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 60 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Castration Resistant Metastatic Prostate Cancer
Interventions: Testosterone cypionate, Enzalutamide, Testosterone Enanthate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more

Conditions: Urinary Tract Infections, Vaginal Flora Imbalance
Interventions: BioNourish; Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: Up to 89 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Pleuropulmonary Blastoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Ifosfamide, Doxorubicin; Drug
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2035
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Traumatic Brain Injury
Interventions: SofPulse; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Infertility
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lumbar Spinal Stenosis
Interventions: Amniotic Fluid Allograft, Dexamethasone sodium phosphate; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Autism Spectrum Disorder
Interventions: Folinic Acid, Placebo; Drug · Other
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Phoenix, Arizona • Atlanta, Georgia • Lexington, Massachusetts + 1 more

Conditions: Cough Reflex Sensitivity
Interventions: diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo, dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Meningeal Neoplasms
Interventions: Intrathecal (injected into the spinal fluid) DepoCyt, Intrathecal methotrexate, Intrathecal cytarabine (also known as ara-C); Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 21
States / cities: Phoenix, Arizona • Berkeley, California • Los Angeles, California + 18 more

Conditions: Shock
Interventions: Cheetah NICOM® PLRT, USCOM ® (Ultrasound Cardiac Output Monitor), Inferior Vena Cava (IVC) Ultrasound Collapsibility, CURVES Questionnaire, Lactate Clearance, 500ml Normal Saline Bolus, Clinician Discretion Intravenous Fluid Management; Device · Behavioral · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lupus Erythematosus, Systemic
Interventions: Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 11
States / cities: Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more

Conditions: Knee Osteoarthritis
Interventions: Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline; Device · Drug
Lead sponsor: Dustin L. Richter, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Radiation Retinopathy
Interventions: 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP); Drug · Procedure
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Katy, Texas + 1 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Fluid Management Intervention; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: Up to 12 Hours
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: New York, New York • Lawton, Oklahoma

Conditions: Alzheimer Disease
Interventions: Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo; Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more

Conditions: Overweight, Autism Spectrum Disorder
Interventions: Metformin, Placebo; Drug
Lead sponsor: Holland Bloorview Kids Rehabilitation Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee

Search by objective public record fields.

Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

DyeVert™ Plus Contrast Reduction System Multicenter Observational Study

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Clinical Investigation on the Effects of a Vegetable Juice Treatment

Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.

Busulfan and Cyclophosphamide Followed By ALLO BMT

LOSS- Louisiana Obese Subjects Study

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

Vaginal Care System for Menopausal Women With Urinary Tract Infections

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

NSI Pulsed Electromagnetic Field (PEMF) Biomarker Study

Infertility Markers in Serum, Urine, and Follicular Fluid

Sterile Amniotic Fluid Filtrate Epidural Injection.

Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo

DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor

Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

Fluid Restriction in Respiratory Distress of the Newborn

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)